SAN DIEGO, Feb. 8, 2013 /PRNewswire/ -- GenomeDx Biosciences today announced that four posters highlighting the performance and clinical utility of its Decipher™ test will be presented at the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). Decipher is a transformative genomic decision tool that provides accurate and actionable information to forecast patients that are at risk for lethal prostate cancer. Abstracts will be made available to the public on February 12 at 6:00 p.m. ET. The conference is taking place February 14-16 in Orlando, Florida.
The schedule for the Decipher poster presentations at ASCO GU follows:
Thursday, February 14, 11:45 a.m. to 1:15 p.m. and 5:05 p.m. to 6:35 p.m. Gatlin Ballroom B
General Poster Session A: Prostate Cancer
- Abstract #36: Validation of a Genomic Classifier that Predicts Metastatic Disease Progression in Men with High Risk Pathological Features Post-prostatectomy
- Abstract #52: Validation of a Genomic Classifier that Predicts Metastatic Disease Progression in Men with Biochemical Recurrence Post Radical Prostatectomy
- Abstract #60: Combined Value of Genomic Biomarkers and CAPRA-S in Predicting Prostate Cancer Death in a High-Risk Surgical Cohort
Friday, February 15, 12:15 p.m. to 1:45 p.m. and 5:15 p.m. to 6:45 p.m. Gatlin Ballroom B
General Poster Session B: Prostate, Penile, Urethral and Testicular Cancer, and Urothelial Carcinoma
- Abstract #196: Evaluation of a Genomic-based Prognostic Test for Metastasis in High-risk Post-prostatectomy Patients: Does it Impact Physician Decision Making?
Decipher™ is a transformative prognostic test that provides a direct measure of the true biological risk of lethal prostate cancer independent of PSA and other risk factors. Decipher measures the expression levels of multiple markers associated with aggressive prostate cancer and provides additional information about a patient's risk of disease progression after surgery (radical prostatectomy). When used in conjunction with conventional risk assessment tools, Decipher has the potential to more accurately stratify a patient's risk for developing recurrent or metastatic cancer following radical prostatectomy.
About GenomeDx Biosciences
GenomeDx Biosciences develops and commercializes genomic tests for prostate and other urologic cancers that have a real impact on treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs. The company's first test, Decipher™, is a transformative prognostic test that provides a direct measure of the true biological risk of lethal metastatic prostate cancer independent of PSA and other risk factors. GenomeDx is based in San Diego, California and Vancouver, Canada. More information is available at www.genomedx.com.